247 related articles for article (PubMed ID: 36517487)
1. Management of patients with lower-risk myelodysplastic syndromes.
Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N
Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487
[TBL] [Abstract][Full Text] [Related]
2. Raising the bar for lower-risk myelodysplastic syndromes.
Venugopal S; Sekeres MA
Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
Stahl M; Zeidan AM
Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
[TBL] [Abstract][Full Text] [Related]
4. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
[TBL] [Abstract][Full Text] [Related]
5. What constitutes meaningful improvement in myelodysplastic syndromes?
Chandhok NS; Sekeres MA
Leuk Lymphoma; 2022 Nov; 63(11):2528-2535. PubMed ID: 35699987
[TBL] [Abstract][Full Text] [Related]
6. [Current treatment strategies for myelodysplastic syndromes].
Suzuki T
Rinsho Ketsueki; 2015 Oct; 56(10):1985-95. PubMed ID: 26458437
[TBL] [Abstract][Full Text] [Related]
7. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
[TBL] [Abstract][Full Text] [Related]
8. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic syndromes: clinical practice guidelines in oncology.
Greenberg PL; Attar E; Bennett JM; Bloomfield CD; Borate U; De Castro CM; Deeg HJ; Frankfurt O; Gaensler K; Garcia-Manero G; Gore SD; Head D; Komrokji R; Maness LJ; Millenson M; O'Donnell MR; Shami PJ; Stein BL; Stone RM; Thompson JE; Westervelt P; Wheeler B; Shead DA; Naganuma M
J Natl Compr Canc Netw; 2013 Jul; 11(7):838-74. PubMed ID: 23847220
[TBL] [Abstract][Full Text] [Related]
10. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
11. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
13. Novel combinations to improve hematopoiesis in myelodysplastic syndrome.
Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC
Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634
[TBL] [Abstract][Full Text] [Related]
14. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
15. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
17. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
18. Targeting inflammation in lower-risk MDS.
Gonzalez-Lugo JD; Verma A
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):382-387. PubMed ID: 36485128
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA; Taylor J
JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
[TBL] [Abstract][Full Text] [Related]
20. [Prognosis and Therapy of Myelodysplastic Syndrome].
Bonadies N
Ther Umsch; 2022; 79(2):93-105. PubMed ID: 35291847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
